Search PubMedSearch

Biomedical subjects

Giovana Tardin Torrezan

Publications and source records attributed to Giovana Tardin Torrezan.

2 recordsLinked to original sources

Rare solid tumours as indicators of hereditary cancer syndromes.

Rare tumours are variously defined but usually affect not more than 1 in 100000 people. They can be present at birth, in childhood or later in life. The diagnosis of a rare tumour can sometimes point to an underlying hereditary condition, and one should take into account important considerations that can increase suspicion of a genetic cause of the disease. While some rare neoplasms are highly specific of a hereditary tumour susceptibility syndrome (and can be almost pathognomonic), thus prompting a direct genetic evaluation, most rare neoplasms may appear within the context of multi-tumour susceptibility syndromes, and here they add important weight to the global assessment when considering a genetic referral. Despite their low frequency, novel associations between rare neoplasms and hereditary conditions continue to emerge, although a solid association is often lacking. On the contrary, some infrequent tumours are nearly always non-hereditary (sporadic) in nature. Of note, the definition of rare tumours should be age-adjusted as paediatric tumours are by definition rare when compared with adult tumours in absolute terms. Therefore, in this review, in the paediatric section, we focus on tumours that occur rarely in childhood. This can include cancers that typically occur in adults, but in this case, it appears in a child. Both situations are a strong indication for genetic testing. In this review, we described different scenarios in which rare neoplasms can serve as indications (or not) for an underlying inherited cancer susceptibility.

Humans

Analysis of structure and conservation for supporting functional evaluation of PMS2 missense variants.

Germline defects in mismatch repair (MMR) genes are known to significantly increase the risk of developing certain types of cancers, notably colorectal and endometrial cancers. These conditions are characterized under Lynch syndrome. Accurate diagnosis of this predisposition, along with meaningful predictive testing for family members, necessitates the identification of pathogenic variants. However, classifying small coding genetic variants identified in cancer patients is very challenging, specifically in the case of PMS2 variants, since PMS2 pathogenic variants display a lower penetrance and less severe phenotype and therefore a lower tumor burden in affected families. We have assembled clinical data on four PMS2 missense variants of uncertain significance (VUS) identified in 23 patients (p.(Asp286Gly), p.(Asn335Ser), p.(Ile679Thr) and p.(Arg799Trp)). For these variants, functional testing was performed (RNA splicing, protein stability and catalytic activity). Since many protein ortholog sequences and accurate predictive models from AlphaFold2 are available, we also included a systematic analysis of residue conservation and structural role (ConStruct assessment). Overall, our findings indicate that p.(Asp286Gly) and p.(Arg799Trp) behave similarly to wild-type PMS2 and are thus probably neutral. In contrast, p.(Asn335Ser) and p.(Ile679Thr) conferred defects in protein expression or MMR activity. These could be explained by the relevant roles of these amino acids in MLH1-PMS2-N-terminal dimerization (p.Asn335) and C-terminal dimerization (p.Ile679). Our data thus suggest that p.(Asp286Gly) and p.(Arg799Trp) are benign, while the tumor risk in the other two variants remains to be established. Taken together, we suggest roadmaps for the individualized evaluation of difficult uncertain variants by comprising information from all available sources.

Humans